**Normal cervical epithelium**

**HPV-infected cervical cells**

**CIN1 or LSIL** (low-grade intraepithelial lesions)

**CIN2 or HSIL** (high-grade intraepithelial lesions)

**CIN3+ or HSIL** (high-grade intraepithelial lesions)

**Cervical carcinoma**

---

**mRNA and Cervical Disease**

The APTIMA® HPV Assay detects E6/E7 viral mRNA from 14 high-risk types of human papillomavirus in cervical specimens (ThinPrep® Pap Test vials containing PreservCyt® Solution collected with broom-type or cytobrush/spatula devices). The test is indicated to screen women ≥21 years with ASCUS cytology to determine the need for colposcopy, and to screen women ≥30 years for high-risk HPV types. This information with cytology history, other risk factors, and guidelines may be used to manage patients. See www.hologic.com for more details.

---

**With the FDA-approved APTIMA® HPV test, you can focus on more clinically relevant results**

**The APTIMA® HPV test**

---

**E6/E7 mRNA levels**

---

**HPV mRNA delivers significantly less false positives than DNA—up to 40% fewer.**

---

The APTIMA® HPV Assay detects E6/E7 viral mRNA from 14 high-risk types of human papillomavirus in cervical specimens (ThinPrep® Pap Test vials containing PreservCyt® Solution collected with broom-type or cytobrush/spatula devices). The test is indicated to screen women ≥21 years with ASCUS cytology to determine the need for colposcopy, and to screen women ≥30 years for high-risk HPV types. This information with cytology history, other risk factors, and guidelines may be used to manage patients. See www.hologic.com for more details.

---

**References:**


9. SonoraQuest.com

Sonora Quest Laboratories, the associated logo and marks are the registered trademarks of Sonora Quest Laboratories. All third party marks — ‘©’ and ‘™’ — are the property of their respective owners. © 2015 Sonora Quest Laboratories. All rights reserved. 0415
The APTIMA® HPV test

Highly sensitive and specific

Offers excellent sensitivity...
so you can help minimize false-negative results

The APTIMA® HPV Assay, utilizing mRNA, has shown sensitivity comparable to common DNA-based tests.¹⁻¹¹

![Clinical Sensitivity Graph]

Sensitivity for CIN3 and more severe lesions

Offers increased specificity, decreasing potential harms¹

Fewer false-positive results¹

The APTIMA® HPV Assay has been shown to produce up to 40% fewer false-positive test results¹:
- Decreasing difficult patient conversations
- Decreasing the potential for over-treatment

The HPV result serves as the gatekeeper in the decision to advance to colposcopy.

Co-testing with Confidence

The HPV mRNA assay provides clinicians greater confidence in patient management, helping reduce the complaints that arise from the performance of unnecessary colposcopies and costly medical procedures.¹³

Pap with HPV Co-testing for Women 30–65 Years of Age

The best way to identify women most at risk of cervical cancer

![HPV Co-testing Diagram]

Published guidelines recommend the use of HPV co-testing in women ages 30–65. Persistent HPV infections occur more frequently in women age 30 or older.

The HPV result serves as the gatekeeper in the decision to advance to colposcopy.

- FDA-approved for use with ThinPrep®
- Complies with cervical cancer screening guidelines*
- Offers excellent sensitivity*
- Same price and coverage as DNA-based HPV tests*
- Offers increased specificity*
- No increased costs to you or your patients*
The APTIMA® HPV test

Highly sensitive and specific

Offers excellent sensitivity... so you can help minimize false-negative results

The APTIMA® HPV Assay, utilizing mRNA, has shown sensitivity comparable to common DNA-based tests.

Clinical Sensitivity

![Graph showing clinical sensitivity for referral and screening populations.]

Offers increased specificity, decreasing potential harms

Fewer false-positive results

The APTIMA® HPV Assay has been shown to produce up to 40% fewer false-positive test results:

- Decreasing difficult patient conversations
- Decreasing the potential for over-treatment

Pap with HPV Co-testing for Women 30–65 Years of Age

The best way to identify women most at risk of cervical cancer

- Normal Cytology
- ASC-US Cytology
- HPV+
- HPV-
- 1-year follow-up
- 5-year follow-up
- Colposcopy

Published guidelines recommend the use of HPV co-testing in women ages 30–65. Persistent HPV infections occur more frequently in women age 30 or older.

The HPV result serves as the gatekeeper in the decision to advance to colposcopy.

Co-testing with Confidence

- FDA-approved for use with ThinPrep
- Offers excellent sensitivity
- Complies with cervical cancer screening guidelines
- Same price and coverage as DNA-based HPV tests
- Offers increased specificity
- No increased costs to you or your patients
The APTIMA® HPV Test

The future of HPV testing is here

With the FDA-approved APTIMA® HPV test, you can focus on more clinically relevant results

### Transition to APTIMA® Made Easy

<table>
<thead>
<tr>
<th>Test Name(s)</th>
<th>Test Code(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pap, ThinPrep® w/reflex HPV mRNA if ASC-US</td>
<td>704</td>
</tr>
<tr>
<td>Pap, ThinPrep® w/reflex HPV mRNA if ASC-US &amp; CT/NG</td>
<td>704 &amp; 803509</td>
</tr>
<tr>
<td>Women 30-65 (Pap &amp; APTIMA® HPV mRNA co-testing)</td>
<td>719</td>
</tr>
<tr>
<td>Pap, ThinPrep® w/HPV mRNA</td>
<td>719</td>
</tr>
<tr>
<td>Pap, ThinPrep® w/HPV mRNA &amp; CT/NG</td>
<td>719 &amp; 803509</td>
</tr>
<tr>
<td>Pap, ThinPrep® w/HPV mRNA w/reflex to Genotypes 16, 18/45 if Pap is Negative and HPV is Positive</td>
<td>435</td>
</tr>
</tbody>
</table>

### Out-of-the-Vial Testing

- Chlamydia trachomatis (CT), ThinPrep® Vial: 906394
- Neisseria gonorrhoeae (NG), ThinPrep® Vial: 906395
- CT/NG, ThinPrep® Vial: 803509
- HPV mRNA: 718
- HPV mRNA w/reflex to Genotypes 16, 18/45 if HPV is Positive: 438
- HPV Genotypes 16, 18/45: 906546

### HPV mRNA delivers significantly less false positives than DNA—up to 40% fewer.

- HPV mRNA assay is more sensitive than the Hybrid Capture 2 assay.

### References

8. SonoraQuest.com - Sonora Quest Laboratories, the associated logo and marks are the registered trademarks of Sonora Quest Laboratories. All third party marks — ‘©’ and ‘™’ — are the property of their respective owners. © 2015 Sonora Quest Laboratories. All rights reserved. 0415